News | Prostate Cancer | April 27, 2023

The abstract data presented at American Urological Association's 2023 Annual Meeting indicates the AI-powered platform shows promise as a means of predicting extracapsular extension risk prediction, potentially improving treatment planning and patient outcomes 

The abstract data presented at American Urological Association's 2023 Annual Meeting indicates the AI-powered platform shows promise as a means of predicting extracapsular extension risk prediction, potentially improving treatment planning and patient outcomes

April 27, 2023 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, presented significant findings from a recent study evaluating extracapsular risk assessments using its AI-powered prostate cancer management platform, Unfold AI, at the American Urological Association’s (AUA) 2023 Annual Meeting. The study compares the use of Avenda Health’s AI-generated extracapsular extension (ECE) risk assessments to conventional methodology, such as MRI or pathology evaluation. The study indicates clinicians equipped with Unfold AI can more precisely predict extraprostatic disease extensions. This knowledge can help doctors more effectively manage prostate cancer and more accurately define the extent of cancer for treatment planning, potentially improving patient outcomes and quality of life.   

ECE refers to cancer growth beyond the prostate gland and into the surrounding soft tissue. When this occurs it can be associated with a higher risk of positive surgical margins leading to increased risk of recurrence or metastatic disease. The presence of ECE is critical to determining the best course of action for treatment and risk to quality of life among prostate cancer patients. Unlike standard practice, AI can combine multi-modal data to map cancer risk in 3D. This study indicated this approach shows promise as a means of accurate ECE prediction. 

The study’s data was collected from the University of California, Los Angeles, consisting of 121 patients who received radical prostatectomy over four years. In the study, patient-level ECE prediction using AI is significantly higher (0.88) than current standards of testing, including MRI (0.71), Gleason Grade (GG) (0.68), and PSA (0.60). Overall, the study showed AI correlates with risk of cancer outside the prostate better than MRI, GG and PSA. 

“These findings are an impressive and exciting new development in the prostate cancer space. Determination of ECE is critical for surgical planning and suitability for localized therapy. This will aid urologists in determining the best possible intervention for each patient, ensuring they can have a better quality of life post-treatment,” said Shyam Natarajan, PhD, co-founder and CEO of Avenda Health. “We aim to democratize personalized prostate cancer care and this study indicates Unfold AI is a powerful tool in making this a reality.” 

Unfold AI received 510(k) clearance by the U.S. Food and Drug Administration (FDA) in December 2022.  

For more information: avendahealth.com 


Related Content

News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | Enterprise Imaging

December 6, 2023 — NVIDIA launched a cloud service for medical imaging AI to further streamline and accelerate the ...

Time December 06, 2023
arrow
News | Ultrasound Imaging

December 6, 2023 — Clarius Mobile Health has been awarded a Technology Breakthrough Designation in the Ultrasound ...

Time December 06, 2023
arrow
News | Digital Pathology

December 6, 2023 — One of the largest independent pathology service providers in the United States, CellNetix Pathology ...

Time December 06, 2023
arrow
News | Artificial Intelligence

December 5, 2023 — Radiology is under severe economic pressure as reimbursement rates fall for many common scans. At the ...

Time December 05, 2023
arrow
News | Artificial Intelligence

December 5, 2023 — Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro, the next-generation AI software for brain ...

Time December 05, 2023
arrow
News | Pediatric Imaging

December 1, 2023 — The Radiation Oncology Program at Children’s Hospital Los Angeles is one of only a few in the country ...

Time December 01, 2023
arrow
News | RSNA

December 1, 2023 — Royal Philips, a global leader in health technology, put patients and healthcare providers center ...

Time December 01, 2023
arrow
News | RSNA

December 1, 2023 —Nuance Communications, Inc., a Microsoft Company, during the 2023 Radiological Society of North ...

Time December 01, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
Subscribe Now